Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Tweets that tell a story: a new approach to boosting HPV vaccination

NCT ID NCT05204030

Prevention Sponsor: University of Arkansas, Fayetteville Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 27, 2026 · Last updated Jul 28, 2026 · Updated 1 time

Summary

This trial investigates whether narrative (story-based) messages on Twitter are more effective than factual messages at encouraging parents to vaccinate their children against HPV. Parents of children aged 9–14 who have not started the HPV vaccine series will be randomly assigned to see either storytelling or fact-based tweets. The study measures whether the messages increase empathy, engagement, and ultimately, vaccination rates.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
HPV Twitter Education Program - Narrative and Non-Narrative messages
What this could lead to
If storytelling on social media proves more effective, it could offer a low-cost way to boost HPV vaccination rates and reduce vaccine-preventable cancers.
What could go wrong
This is a small, early-stage trial with only 28 participants, so results may not apply broadly. Social media engagement does not always translate into actual vaccination.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

28 people

The number who actually took part.

Started

Dec 2021

Finished

Aug 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: The study population includes parents who have children ages 9-14. All participants will be 18 years of age or older, and we will specifically target parents ages 25 and older. Eligibility for enrollment in the study will be limited to the following criteria: 1. Adults 18 years of age and older; 2. Utilizes Twitter, a social media platform; 3. Has a child aged 9-14; 4. Child has not started the 2-dose HPV vaccination series; 5. Has no child who has completed any dose HPV vaccination series; 6. Has a well-care visit scheduled for their child before December, 2022. Exclusion Criteria: 1. Any adult who does not have a child 9-14 years of age; 2. Any adult who does not indicate some level of participation in Twitter; 3. Any adults who indicates a high level of anti-vaccine sentiment (assessed by vaccine hesitancy questions asked in the screener).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Human papilloma virus are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Vaccine-Preventable Diseases human papilloma virus infection prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Human papilloma virus Vaccine-preventable diseases

Contacts and locations

Locations

  • University of Arkansas

    Fayetteville, Arkansas, 72701, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.